HighPoint Blog

On July 18, 2018, the FDA published its guidance for biosimilars, “Labeling for Biosimilar Products.” This guidance provides an overview of the FDA’s recommendations for biosimilar labeling, so that prescribers can make informed decisions. The FDA states the intent of the guidance is to help manufacturers “develop draft labeling for proposed biosimilar products for submission in an application...

Read More

At the simplest, Relative Value Units (RVUs) measure the value used in Medicare reimbursements for physician services.

Read More

Co-authored by: Suzanne Kunze, Norita Wilson, and Lori Harris

In our previous blog, you learned about the strengths of both NCQA and URAC accreditation. Now we’ll look at how you can prepare for accreditation.

Read More

In a world of frequent biopharma mergers and divestitures, the optimal size and structure for a pharma company’s contract operations department is a moving target. Whether you’re setting up a new department or adjusting an existing one, meeting these shifting expectations is a challenge. There is typically no single way to determine your company’s unique best fit – one that balances management...

Read More

Co-authored by: Suzanne Kunze, Norita Wilson, and Lori Harris

Health plans will look to two prominent and nationally recognized organizations, NCQA or URAC, when they are seeking accreditation. Accreditation provides an impartial opinion on a health plan’s quality. URAC or NCQA accredit a health plan when it has been determined its practices meet national standards.

Read More

Recent Posts

Tag